Browse News
Filter News
Found 409 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Pelthos Therapeutics Establishes Board of Directors
4/16/2024
Pelthos Therapeutics today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.
-
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
4/15/2024
Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open.
-
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
4/9/2024
Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
-
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
3/25/2024
Sagimet Biosciences Inc. today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024.
-
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
2/29/2024
Aurinia Pharmaceuticals Inc. today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program.
-
Aurinia to Participate in Upcoming Investor Healthcare Conferences
2/27/2024
Aurinia Pharmaceuticals Inc. today announced that management will be participating in the following upcoming investor conferences during the month of March.
-
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
2/22/2024
Kane Biotech Inc. Dr. Robert Huizinga was elected as a director of the Company.
-
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
2/15/2024
Aurinia Pharmaceuticals Inc. provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company’s strategic review.
-
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
2/5/2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open.
-
Kane Biotech Announces Special Meeting of Shareholders - Jan 18, 2024
1/18/2024
Kane Biotech Inc. announces that on February 20, 2024, the Company will hold a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director of the Company.
-
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
1/5/2024
Aurinia Pharmaceuticals Inc. provided an update on its 2023 fourth quarter and full year business performance.
-
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
12/20/2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases.
-
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
11/13/2023
Aurinia Pharmaceuticals Inc. announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application for voclosporin for the treatment of lupus nephritis with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis.
-
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
11/7/2023
Aurinia Pharmaceuticals Inc., announced the presentation of five studies at the annual American College of Rheumatology Convergence 2023 taking place in San Diego, CA, November 10-15.
-
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
11/2/2023
Aurinia Pharmaceuticals Inc. issued its financial results for the three and nine months ended September 30, 2023. Amounts are expressed in U.S. dollars.
-
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
11/2/2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of nine studies (one oral and eight posters) at the annual American Society of Nephrology Kidney Week 2023 Convergence taking place in Philadelphia, PA, November 2-5.
-
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
10/26/2023
Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology for the management of systemic lupus erythematosus based on emerging new evidence, including a new treatment paradigm for lupus nephritis.
-
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
10/19/2023
Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open.
-
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
10/13/2023
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”) today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), taking place November 10-15 in San Diego, California.